FY2025 · ended Dec 31, 2025 · Revenue $534.53M, +14.9% YoY · Filed Feb 19, 2026
AtriCure, Inc. (ATRC) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $534.5 million and a net loss of $11.4 million. Free cash flow was $48.3 million. As of Sep 30, 2026 it held $187.0 million in cash and investments and $96.7 million in total debt.
Revenue (TTM)
$589.80M
+13.8% vs year-ago TTM
Net income (TTM)
$14.88M
+151.7% vs year-ago TTM
Operating cash flow (TTM)
$68.55M
+58.9% vs year-ago TTM
Free cash flow (TTM)
$52.94M
+60.4% vs year-ago TTM
EPS (TTM)
$0.30
+150.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
49.81M
+1.9% vs prior year
Net cash
$90.32M
as of Sep 30, 2026
Operating margin
2.9%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- ATRC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Mason, OH
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1323885
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $534.5M | $465.3M | $399.2M | $330.4M | $274.3M |
| Operating income | -$9.4M | -$40.0M | -$26.7M | -$42.7M | $55.2M |
| Net income | -$11.4M | -$44.7M | -$30.4M | -$46.5M | $50.2M |
| Diluted EPS | -$0.24 | -$0.95 | -$0.66 | -$1.02 | $1.09 |
| Operating cash flow | $57.3M | $12.2M | $4.5M | -$22.1M | -$13.8M |
| Free cash flow | $48.3M | $745,000 | -$7.5M | -$39.0M | -$23.5M |
| Total assets | $654.2M | $609.3M | $613.9M | $585.4M | $615.3M |
| Total liabilities | $162.2M | $148.4M | $147.8M | $128.7M | $131.6M |
| Stockholders' equity | $491.9M | $461.0M | $466.2M | $456.8M | $483.8M |
| Cash and investments | $167.4M | $122.7M | $137.3M | $172.6M | $223.4M |
| Total debt | $76.4M | $76.5M | $74.5M | $74.4M | $75.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 3, 2026 | Nov 3, 2026 |
| 10-Q | Quarterly report | Jul 27, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 23, 2026 | Jul 23, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
May 19, 2026 | May 18, 2026 |
| 10-Q | Quarterly report | May 6, 2026 | Mar 31, 2026 |
All 1003 AtriCure, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.